Keck School Faculty

Caroline Irene Piatek
Caroline Irene Piatek
Assistant Professor of Clinical Medicine;Hematology Fellowship Program Director;Service Chief for Hematology at LAC+USC
1441 Eastlake Ave. Health Sciences Campus Los Angeles
Dr. Piatek's research interests include cancer-associated thrombosis and staging studies in breast cancer. She joined the Division of Hematology after serving as Chief Hematology Fellow in the Hematology/Oncology Fellowship at Keck School of Medicine of USC. \n\nDr. Piatek earned her medical degree from Creighton University School of Medicine. She then performed her internal medicine internship and residency at Keck School of Medicine of USC, followed by a Hematology/Oncology Fellowship.

Keck School of Medicine of USC: Hematology Chief Fellow, 2014-2015

American Society of Clinical Oncology: Conquer Cancer Foundation Merit Award, 2014

USC: Medical Oncology Fellow Research Award, 2012-2013

Creighton University School of Medicine: Medical Dean's Educational Assistance Scholarship, 2009

Claremont McKenna College: Best Biology Senior Thesis, 2005

Claremont McKenna College: Honors in Biology, 2005

Claremont McKenna College: Magna Cum Laude, 2005

Claremont McKenna College: Dean's List (all semesters), 2001-2005

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria PLoS One. 2020; 15(9):e0237497. . View in PubMed

A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia Acta Haematol. 2020; 143(3):244-249. . View in PubMed

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study Blood. 2019 02 07; 133(6):540-549. . View in PubMed

Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia Case Rep Oncol. 2018 Sep-Dec; 11(3):880-882. . View in PubMed

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome Acta Haematol. 2017; 138(3):129-137. . View in PubMed

Value of routine staging imaging studies for patients with stage III breast cancer J Surg Oncol. 2016 Dec; 114(8):917-921. . View in PubMed

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin Thromb Res. 2016 Apr; 140 Suppl 1:S174. . View in PubMed

Management of immune-mediated cytopenias in pregnancy Autoimmun Rev. 2015 Sep; 14(9):806-11. . View in PubMed

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians Korean J Fam Med. 2015 Sep; 36(5):197-202. . View in PubMed

Thrombocytopenia: optimizing approaches in cancer patients Oncology (Williston Park). 2015 Apr; 29(4):297-8. . View in PubMed

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. . View in PubMed

Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature Hum Pathol. 2014 Nov; 45(11):2183-91. . View in PubMed

Unsuspected pulmonary embolism: impact on mortality among cancer patients Curr Opin Pulm Med. 2012 Sep; 18(5):406-9. . View in PubMed

Treating venous thromboembolism in patients with cancer Expert Rev Hematol. 2012 Apr; 5(2):201-9. . View in PubMed

Genetic screens for enhancers of brahma reveal functional interactions between the BRM chromatin-remodeling complex and the delta-notch signal transduction pathway in Drosophila Genetics. 2005 Aug; 170(4):1761-74. . View in PubMed

Powered by SC CTSI
Go to Top